Nakandakare E R, Garcia R C, Carré J M, Zerbinatti C V, Oliveira H C, Quintão E C
Arq Bras Cardiol. 1989 May;52(5):291-5.
Lovastatin, a potent inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme-A-reductase, was investigated in a placebo-controlled trial of 26 primary hypercholesterolemic subjects. Drug dosage varied from 20 to 40 mg/d in a single dose on a 12 weeks treatment period. Average plasma cholesterol reduction levels were 17 and 31%, and LDL-cholesterol 24 and 41% on 20 and 40 mg/d respectively. High-density lipoprotein and triglycerides levels did not change significantly. Similar mean decreases in total plasma cholesterol and LDL-cholesterol levels were observed in hypercholesterolemics irrespectively of being of familial origin or not. No serious clinical and laboratory abnormalities were observed. In this study, lovastatin was a well tolerated and effective agent for the treatment of non familial and heterozygous familial hypercholesterolemia.
洛伐他汀是一种强效的3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂，在一项针对26名原发性高胆固醇血症患者的安慰剂对照试验中进行了研究。在为期12周的治疗期间，药物剂量为每日20至40毫克，单次给药。每日服用20毫克和40毫克时，血浆胆固醇平均降低水平分别为17%和31%，低密度脂蛋白胆固醇分别降低24%和41%。高密度脂蛋白和甘油三酯水平没有显著变化。无论是否为家族性高胆固醇血症患者，高胆固醇血症患者的血浆总胆固醇和低密度脂蛋白胆固醇水平均出现了类似的平均下降。未观察到严重的临床和实验室异常情况。在本研究中，洛伐他汀是一种耐受性良好且有效的药物，可用于治疗非家族性和杂合子家族性高胆固醇血症。
